Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ)...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of GUARD.ST is 1.8 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati
Buy
Sell